A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 138,800 shares of AXSM stock, worth $12.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
138,800
Previous 81,500 70.31%
Holding current value
$12.6 Million
Previous $6.56 Million 90.11%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.93 - $95.84 $35.4 Million - $43 Million
-448,555 Reduced 59.55%
304,682 $27.4 Million
Q2 2024

Aug 14, 2024

SELL
$65.72 - $80.5 $25.7 Million - $31.4 Million
-390,407 Reduced 34.14%
753,237 $60.6 Million
Q1 2024

May 15, 2024

BUY
$69.39 - $97.64 $3.79 Million - $5.33 Million
54,559 Added 5.01%
1,143,644 $91.3 Million
Q4 2023

Feb 14, 2024

SELL
$57.42 - $83.61 $11.9 Million - $17.3 Million
-206,539 Reduced 15.94%
1,089,085 $86.7 Million
Q3 2023

Nov 14, 2023

BUY
$69.25 - $82.21 $58.3 Million - $69.2 Million
841,306 Added 185.18%
1,295,624 $90.6 Million
Q2 2023

Aug 14, 2023

BUY
$58.41 - $90.35 $14.9 Million - $23.1 Million
255,297 Added 128.28%
454,318 $32.6 Million
Q1 2023

May 15, 2023

SELL
$58.39 - $75.0 $9.62 Million - $12.4 Million
-164,720 Reduced 45.28%
199,021 $12.3 Million
Q4 2022

Feb 14, 2023

SELL
$39.94 - $79.72 $6.69 Million - $13.4 Million
-167,596 Reduced 31.54%
363,741 $28.1 Million
Q3 2022

Nov 14, 2022

BUY
$36.06 - $69.85 $2.9 Million - $5.61 Million
80,342 Added 17.81%
531,337 $23.7 Million
Q2 2022

Aug 15, 2022

BUY
$21.74 - $46.75 $4.65 Million - $10 Million
213,982 Added 90.28%
450,995 $17.3 Million
Q1 2022

May 16, 2022

SELL
$23.7 - $41.39 $1.69 Million - $2.95 Million
-71,278 Reduced 23.12%
237,013 $9.81 Million
Q4 2021

Feb 14, 2022

BUY
$30.7 - $43.36 $6,876 - $9,712
224 Added 0.07%
308,291 $11.6 Million
Q3 2021

Nov 15, 2021

SELL
$19.91 - $68.26 $5.21 Million - $17.9 Million
-261,738 Reduced 45.93%
308,067 $10.2 Million
Q2 2021

Aug 16, 2021

BUY
$50.63 - $73.5 $8.13 Million - $11.8 Million
160,511 Added 39.22%
569,805 $38.4 Million
Q1 2021

May 17, 2021

SELL
$55.91 - $81.44 $17.6 Million - $25.6 Million
-314,845 Reduced 43.48%
409,294 $23.2 Million
Q4 2020

Feb 16, 2021

BUY
$66.31 - $86.52 $32.6 Million - $42.6 Million
492,133 Added 212.12%
724,139 $59 Million
Q3 2020

Nov 16, 2020

SELL
$68.34 - $85.84 $15.4 Million - $19.3 Million
-225,068 Reduced 49.24%
232,006 $16.5 Million
Q2 2020

Aug 14, 2020

SELL
$49.87 - $98.69 $15.3 Million - $30.2 Million
-306,420 Reduced 40.13%
457,074 $37.6 Million
Q1 2020

May 15, 2020

BUY
$41.2 - $101.31 $7.66 Million - $18.8 Million
185,851 Added 32.17%
763,494 $44.9 Million
Q4 2019

Feb 14, 2020

BUY
$16.71 - $106.24 $7.58 Million - $48.2 Million
453,636 Added 365.81%
577,643 $59.7 Million
Q3 2019

Nov 14, 2019

BUY
$20.24 - $29.16 $1.67 Million - $2.4 Million
82,473 Added 198.57%
124,007 $2.51 Million
Q2 2019

Aug 14, 2019

BUY
$13.46 - $25.75 $111,152 - $212,643
8,258 Added 24.82%
41,534 $1.07 Million
Q1 2019

May 15, 2019

BUY
$2.63 - $16.34 $46,537 - $289,136
17,695 Added 113.57%
33,276 $0
Q2 2018

Aug 10, 2018

BUY
$2.15 - $3.6 $33,499 - $56,091
15,581 New
15,581 $0

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $3.89B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.